Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD), characterized by dyspnea, chronic cough, and sputum production is one of the leading causes of morbidity and death worldwide.[@CIT0001],[@CIT0002] In Asia, the prevalence of COPD has been reported to be between 5.4% and 13.6% and is increasing.[@CIT0003]--[@CIT0008] A systematic review of patients with COPD in China showed that COPD has a high disease burden resulting in a high economic burden.[@CIT0009]

The Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy recommends long-acting muscarinic antagonist (LAMA) or long-acting β~2~-agonist (LABA) monotherapy as first-line treatment for patients with COPD in all GOLD groups, with the exception of LABA monotherapy in group D.[@CIT0002] The LAMA tiotropium (TIO) significantly improves lung function and health status, and reduces exacerbation rates in patients with COPD.[@CIT0010] However, some limitations have been reported with TIO, including delayed onset of action.[@CIT0011] As such, a number of LAMAs were developed to overcome some of the limitations associated with TIO in order to improve efficacy. One such LAMA is umeclidinium (UMEC), a quinuclidine derivative that is a potent, inhaled LAMA with a prolonged duration of action compared with other anticholinergic agents. Studies have reported that UMEC has similar pharmacokinetic properties in different ethnic populations, including a healthy Chinese population.[@CIT0011] Furthermore, UMEC has demonstrated superior efficacy on lung function compared with TIO.[@CIT0011],[@CIT0012]

UMEC is approved as a maintenance bronchodilator treatment for adult patients with COPD.[@CIT0013],[@CIT0014] Previous studies have demonstrated the efficacy and safety of once-daily UMEC in COPD populations worldwide[@CIT0012],[@CIT0015],[@CIT0016] and one study has reported the efficacy and safety of the UMEC in combination with vilanterol in an Asian population;[@CIT0017] however, there are currently no studies of UMEC monotherapy in patients of Asian origin. A comparison of baseline characteristics in an international COPD trial demonstrated baseline differences between Western and Asian patients, with the Asian study population containing a higher proportion of men, had a lower body mass index, and a higher incidence of exacerbations.[@CIT0018] Study population differences and racial differences in socioeconomic status and clinical practice[@CIT0004],[@CIT0019],[@CIT0020] could influence the relative efficacy and safety of therapy in patients with COPD, and it is therefore important to assess therapies in different ethnic populations. The aim of this study was to evaluate the efficacy and safety of UMEC compared with placebo in Asian patients with COPD.

Methods {#S0002}
=======

Study Design and Treatments {#S0002-S2001}
---------------------------

This 24-week, Phase III, randomized, double-blind, parallel-group study (GSK study number AC117410; NCT02184611) compared the efficacy and safety of UMEC 62.5 mcg with placebo in patients with COPD across 21 centers in China and five centers in the Republic of Korea. The study took place between May 2016 and November 2017. Following screening (Visit 1), patients entered a 7--14-day run-in period before being randomized 2:1 to receive UMEC 62.5 mcg or placebo once daily via the ELLIPTA inhaler for 24 weeks. Following randomization (Day 1, Visit 2), patients attended a further 7 outpatient clinic visits on Days 2, 28, 56, 84, 112, 168, and 169. Additionally, a follow-up telephone call took place 7 days after the end of study treatment. Rescue albuterol was provided to patients for use as needed.

Patients were assigned to treatment using a central random allocation sequence generated by the study statistician using a validated computerized system (RAMOS NG software). The block size for randomization was six, with a ratio of 4:2 for UMEC:placebo. Double-blinding was ensured by using ELLIPTA inhalers containing UMEC or placebo that were identical in appearance. Investigators enrolled the patients and assigned their intervention.

The study was conducted in accordance with the ethical principles of the Declaration of Helsinki, International Council for Harmonisation Good Clinical Practice (GCP), and the applicable country-specific regulatory requirements and study materials (protocol, informed consent) were reviewed and approved by a regional, investigational center ethics committee. The study protocol is available at [<https://www.gsk-studyregister.com>]{.ul}.

Eligibility Criteria {#S0002-S2002}
--------------------

Patients were ≥40 years of age, of Asian ancestry, with a diagnosis of COPD according to the American Thoracic Society/European Respiratory Society definition and were current or former cigarette smokers with a history of ≥10 pack-years. At screening, eligible patients had pre- and post-albuterol forced expiratory volume in 1 s (FEV~1~)/forced vital capacity (FVC) ratio of \<0.70, pre- and post-albuterol FEV~1~ ≤70% predicted, and a Modified Medical Research Council (mMRC) Dyspnea Scale score ≥2. The following concomitant treatments were permitted during the study: study-provided salbutamol (withheld for 4 hrs prior to spirometry testing); theophylline (provided the dose remained stable throughout the study, and was withheld for 12 hrs prior to each clinic visit); ipratropium bromide (provided the dose remained stable throughout the study, andwas withheld for 4 hrs prior to each clinic visit); inhaled corticosteroids (ICS) at a dose of ≤1000 mcg/day of fluticasone propionate or equivalent; mucolytics such as acetylcysteine; medications for rhinitis (eg, intranasal corticosteroids, antihistamines, cromolyn, nedocromil, nasal decongestants); influenza or pneumonia vaccinations; short-term antibiotics; oral anticholinergics for overactive bladder; pulmonary rehabilitation in the maintenance phase; smoking cessation treatment, including a stable regimen of nicotine replacement; and positive airway pressure for sleep apnea.

Patients diagnosed with asthma were excluded, as were those who smoked but used a pipe or cigar only and those who had been hospitalized for COPD or pneumonia in the 12 weeks prior to screening or had undergone lung volume reduction surgery in the 12 months prior to screening. Patients who had clinically significant abnormalities not due to COPD shown by a chest X-ray or computed tomography scan, and those who were unable to withhold albuterol for 4 hrs prior to spirometry testing were also excluded, as were patients on long-term oxygen therapy (\>12 hrs per day) or regular short-acting bronchodilator therapy via a nebulizer, and those who were in the acute phase of a pulmonary rehabilitation program in the 4 weeks prior to Visit 1.

Following the run-in period, patients eligible to be randomized to treatment had to demonstrate a normal pre-dose electrocardiogram, have had no COPD exacerbations (defined as worsening of COPD symptoms requiring additional treatment other than study treatment or rescue albuterol) or lower respiratory tract infections during the run-in period, and have maintained a stable, regular dose of ≤1000 mcg/day fluticasone propionate or equivalent during the run-in period (if using ICS). All patients provided written informed consent.

Patients experiencing a COPD exacerbation requiring treatment with systemic corticosteroids, with prescribed or non-prescribed antibiotics and/or emergency treatment or hospitalization during the study were withdrawn; however, patients with an exacerbation that required treatment with antibiotics alone could continue participating in the study.

Endpoints and Assessments {#S0002-S2003}
-------------------------

The primary efficacy endpoint was change from baseline (CFB) in trough FEV~1~ on Day 169. Secondary endpoints were weighted mean FEV~1~ over 0--6 hrs post dose (measurements obtained at 15 and 30 mins, 1, 3, and 6 hrs after administration of study medication) on Day 1 and Transition Dyspnea Index (TDI) focal score on Day 168. Other efficacy endpoints included proportion of FEV~1~ responders (defined as achieving a ≥100 mL increase from baseline in trough FEV~1~) on Day 169, CFB in trough FEV~1~ and trough FVC on Days 2, 28, 56, 84, 112, and 168, serial FEV~1~ and FVC over 0--6 hrs post-dose on Day 1. All spirometry measurements were collected in the morning, and salbutamol was withheld for at least 4 hrs prior to testing. Trough and pre-dose measurements were collected after a study medication washout period of approximately 24 hrs.

TDI focal score and proportion of TDI responders (defined as a TDI score ≥1 unit) on Days 28, 84, and 168, on-treatment COPD exacerbations, time to first COPD exacerbation and rescue albuterol use (puffs/day, recorded by patients in a diary) over Weeks 1 to 24 were also measured. Additionally, health outcomes assessments included St George's Respiratory Questionnaire (SGRQ) and COPD Assessment Test (CAT), assessed at baseline, Day 28, Day 84, and Day 168. SGRQ responders were defined as patients achieving a decrease from baseline in SGRQ total score ≥4 units and CAT responders were defined as patients achieving a decrease from baseline in CAT score of ≥2 units.

Safety endpoints included the incidence of adverse events (AEs) and serious AEs (SAEs) over the 24-week treatment period.

Statistical Analysis {#S0002-S2004}
--------------------

Sample size calculations estimated that 288 patients needed to be randomized (UMEC n=192, placebo n=96) to provide 156 evaluable patients in the UMEC arm and 78 evaluable patients in the placebo arm (assuming an 18% withdrawal rate) to give 94% power to detect a true treatment difference of 115 mL in trough FEV~1~ on Day 169.

Analyses were conducted in the modified intent-to-treat (mITT) population, which included all patients who were randomized and received at least one dose of randomized study drug.

CFB in trough FEV~1~, trough FVC (measurements taken on Days 2, 28, 56, 84, 112, 168, and 169), SGRQ total score, CAT score (measurements taken on Days 1, 28, 84, and 168) and TDI focal score (measurements taken on Days 28, 84, and 168) were analyzed using mixed model repeated measures, adjusting for treatment, smoking status at screening, country, day, baseline, baseline by day and treatment by day. Weighted mean FEV~1~ over 0--6 hrs post dose on Day 1 and puffs/day of albuterol were analyzed using an analysis of covariance (ANCOVA) model, with covariates of treatment, smoking status at screening, baseline, and country. Serial FEV~1~ and FVC over 0--6 hrs post-dose on Day 1 were analyzed using a repeated measures model, with covariates of treatment, baseline FEV~1~, country, time, time by treatment and time by baseline interactions. The proportions of FEV~1~, TDI, SGRQ, and CAT responders at each visit were analyzed using a logistic regression model with covariates of treatment, baseline, smoking status, and country.

Kaplan--Meier and Cox proportional hazards regression analysis with covariates of treatment, smoking status at screening and country was performed to analyze the incidence of a first COPD exacerbation.

Significance tests were performed at the two-sided 5% alpha level.

Results {#S0003}
=======

Patient Disposition and Demographics {#S0003-S2001}
------------------------------------

Patients were recruited between May 2016 and May 2017, and the final follow-up visit was in November 2017. The mITT population comprised 306 patients of East Asian heritage ([Figure 1](#F0001){ref-type="fig"}), with a mean age (standard deviation \[SD\]) of 65.7 (7.05) years; 290 (95%) patients were male; 205 patients received UMEC and 101 received placebo ([Table 1](#T0001){ref-type="table"}). Demographic and clinical characteristics were similar between the UMEC and placebo treatment groups ([Table 1](#T0001){ref-type="table"}). Use of on-treatment permitted concomitant medications was similar between UMEC and placebo groups ([[Supplementary Table 1](https://www.dovepress.com/get_supplementary_file.php?f=215011.docx)]{.ul}).Table 1Patient Demographics and Baseline CharacteristicsPlaceboUMECn101205Mean age, years (SD)65.7 (7.05)65.5 (6.89)Male, n (%)97 (96)193 (94)Current smoker at screening, n (%)29 (29)64 (31)Mean smoking pack-years (SD)37.2 (18.80)36.8 (16.72)ICS use at screening, n (%)48 (48)100 (49)Mean mMRC dyspnea score (SD)2.2 (0.37)2.2 (0.49)COPD exacerbations in the 12 months prior to pre-screening, n (%) Moderate (required oral/systemic corticosteroids and/or antibiotics)  079 (78)156 (76)  117 (17)34 (17)  23 (3)10 (5)  ≥32 (2)4 (2) Severe (required hospitalization)  087 (86)189 (92)  112 (12)14 (7)  202 (\<1)  \>22 (2)0Mean baseline FEV~1~, mL (SD)1016 (331)1042 (371)^a^Mean % predicted FEV~1~ post-albuterol, % (SD)47.32 (12.52)48.88 (13.61)GOLD stage (% predicted FEV~1~), n (%) Stage I (≥80%)00 Stage II (≥50% to \<80%)44 (44)100 (49) Stage III (≥30% to \<50%)46 (46)86 (42) Stage IV (\<30%)11 (11)19 (9)Mean BDI focal score (SD)6.7 (2.30)6.6 (2.36)[^1][^2] Figure 1Patient disposition.**Abbreviations:** mITT, modified intent-to-treat; UMEC, umeclidinium.

Overall, 257/306 (84%) patients completed the study (placebo n=80/101 \[79%\]; UMEC n=177/205 \[86%\]), and 49/306 (16%) withdrew (placebo n=21/101 \[21%\]; UMEC n=28/205 \[14%\]; [Figure 1](#F0001){ref-type="fig"}). The most common reason for withdrawal in both treatment groups was lack of efficacy (placebo n=11/101 \[11%\]; UMEC n=15/205 \[7%\]).

Efficacy Outcomes {#S0003-S2002}
-----------------

### Lung Function {#S0003-S2002-S3001}

The primary endpoint was met, with CFB in least squares (LS) mean trough FEV~1~ on Day 169 of −22 mL in the placebo arm and 131 mL in the UMEC arm, equating to a clinically meaningful (≥100 mL)[@CIT0021] and statistically significant improvement of 154 mL (95% confidence interval \[CI\]: 113, 194; p\<0.001) ([Table 2](#T0002){ref-type="table"}). At all other time points (Days 2, 28, 56, 84, 112, and 168), CFB in LS mean trough FEV~1~ was statistically significantly in favor of UMEC over placebo (p\<0.001) and treatment differences were clinically meaningful (120--192 mL; [Figure 2A](#F0002){ref-type="fig"}). The odds of achieving a ≥100 mL increase in trough FEV~1~ on Day 169 were significantly higher with UMEC versus placebo (placebo n=18/101 \[18%\], UMEC n=101/203 \[50%\]; odds ratio \[OR\] \[95% CI\] 4.90 \[2.71, 8.87\]; p\<0.001).Table 2Lung Function EndpointsPlaceboUMEC**CFB in Trough FEV~1~ at Day 169**n80176LS mean change, mL (SE)−22 (17)131 (12) Treatment difference vs placebo, mL (95% CI)\
 p-value--154 (113, 194)\
\<0.001**Weighted Mean FEV~1~ Over 0--6 hrs on Day 1**n101203LS mean FEV~1~, mL (SE)1047 (9)1172 (6)LS mean CFB FEV~1~, mL (SE)11 (9)136 (6) Treatment difference vs placebo, mL (95% CI)\
 p-value--125 (103, 147)\
p\<0.001**Serial Mean FEV~1~ Over 0--6 hrs on Day 1**n101203LS mean FEV~1~, mL (SE)1029 (11)1166 (8)LS mean CFB FEV~1~, mL (SE)−4 (11)132 (8) Treatment difference vs placebo, mL (95% CI)\
 p-value--136 (109, 164)\
p\<0.001**Serial Mean FVC Over 0--6 hrs on Day 1**n101203LS mean FVC, mL (SE)2680 (28)2922 (20)LS mean CFB FVC, mL (SE)4 (28)284 (20) Treatment difference vs placebo, mL (95% CI)\
 p-value--242 (175, 310)\
p\<0.001[^3] Figure 2Change from baseline in (**A)** trough FEV~1~ and (**B)** trough FVC.**Abbreviations:** CI, confidence interval; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; LS, least squares; UMEC, umeclidinium.

LS weighted mean FEV~1~ 0--6 hrs post dose on Day 1 increased relative to baseline by 11 mL in the placebo arm and 136 mL in the UMEC arm, giving a clinically meaningful difference of 125 mL in favor of UMEC (95% CI: 103, 147; p\<0.001; [Table 2](#T0002){ref-type="table"}). Similarly, a clinically meaningful difference in favor of UMEC was seen in the CFB in serial FEV~1~ over 0--6 hrs post dose on Day 1, with LS mean changes of 4 mL in the placebo arm and 132 mL in the UMEC arm, equating to a between-treatment difference of 136 mL (95% CI: 109, 164; p\<0.001; [Table 2](#T0002){ref-type="table"}).

A statistically significant difference in CFB in trough FVC was seen in favor of UMEC at all time points ([Figure 2B](#F0002){ref-type="fig"}). Additionally, a clinically meaningful difference in favor of UMEC was seen in the CFB in serial FVC over 0--6 hrs post dose on Day 1, with LS mean increases of 4 mL in the placebo arm and 284 mL in the UMEC arm, equating to a between-treatment difference of 242 mL (95% CI: 175, 310; p\<0.001; [Table 2](#T0002){ref-type="table"}).

### TDI Score {#S0003-S2002-S3002}

LS mean (SD) TDI focal score on Day 168 was 1.6 (0.26; n=80) in the placebo arm, and 2.5 (0.17; n=176) in the UMEC arm, equating to a LS mean treatment difference of 0.9 units in favor of UMEC (95% CI: 0.3, 1.5; p=0.004). The LS mean TDI focal score was also statistically significantly higher in the UMEC versus placebo groups at Day 28 but not Day 84 ([Figure 3](#F0003){ref-type="fig"}).Figure 3TDI focal score at Days 28, 84, and 168.**Abbreviations:** CI, confidence interval; LS, least squares; TDI, Transient Dyspnea Index; UMEC, umeclidinium.

On Day 168, the proportion of TDI responders was statistically significantly higher in the UMEC group compared with the placebo group (66% vs 50%; OR 2.0 \[95% CI: 1.2, 3.4\]; p=0.007), whereas at Days 28 and 84 the difference between treatment groups was not statistically significant ([Table 3](#T0003){ref-type="table"}).Table 3Proportion of TDI Responders (Defined as a TDI Focal Score ≥1 Unit)TDI ResponsePlacebo\
N=101UMEC\
N=205Day 28, n94199Responders, n (%)52 (55)133 (67)UMEC vs placebo odds ratio (95% CI)\
p-value--1.7 (1.0, 2.8)\
p=0.057Day 84, n94198Responders, n (%)54 (57)134 (68)UMEC vs placebo odds ratio (95% CI)\
p-value--1.6 (0.9, 2.7)\
p=0.078Day 168, n94199Responders, n (%)47 (50)132 (66)UMEC vs placebo odds ratio (95% CI)\
p-value--2.0 (1.2, 3.4)\
p=0.007[^4]

### COPD Exacerbations {#S0003-S2002-S3003}

On-treatment COPD exacerbations were experienced by 19/101 (19%) patients in the placebo arm and 24/205 (12%) patients in the UMEC arm. The probability of having a first COPD exacerbation was lower in the UMEC arm (12.5%) compared with the placebo arm (20.2%). The hazard ratio was directionally in favor of UMEC versus placebo (0.6 \[95% CI: 0.3, 1.1\]) but was not statistically significant (p=0.078). The majority of exacerbations were treated with antibiotics and/or steroids. Few exacerbations required hospitalization (placebo 4/21 \[19%\] exacerbations, UMEC 5/28 \[18%\] exacerbations).

Rescue Medication Use {#S0003-S2003}
---------------------

The mean CFB in the number of puffs of rescue medication per day over Weeks 1 to 24 was statistically significantly in favor of UMEC over placebo (−0.5; 95% CI:-0.9, −0.1; p=0.008; [Table 4](#T0004){ref-type="table"}).Table 4Rescue Medication Use, Mean SGRQ Total Score and CAT ScorePlacebo\
N=101UMEC\
N=205**Rescue Medication Use**Weeks 1--24, n86177LS mean number of puffs of rescue medication per day (SE)1.7 (0.16)1.2 (0.11)LS mean CFB in number of puffs of rescue medication per day (SE)0.1 (0.16)−0.4 (0.11) Treatment difference vs placebo, number (95% CI)\
 p-value--−0.5 (−0.9, −0.1)\
p=0.008**SGRQ Total Score**Day 28, n91188LS mean total score (SE)40.01 (1.174)35.62 (0.813)LS mean CFB (SE)−1.45 (1.174)−5.84 (0.813) Treatment difference vs placebo, number (95% CI)\
 p-value--−4.39 (−7.21, −1.58)\
p=0.002Day 84, n84183LS mean total score (SE)39.00 (1.268)34.40 (0.860)LS mean CFB (SE)−2.46 (1.268)−7.05 (0.860) Treatment difference vs placebo, number (95% CI)\
 p-value--−4.59 (−7.61, −1.57)\
p=0.003Day 168, n78176LS mean total score (SE)37.14 (1.316)34.12 (0.882)LS mean CFB (SE)−4.31 (1.316)−7.34 (0.882) Treatment difference vs placebo, number (95% CI)\
 p-value--−3.03 (−6.15, 0.10)\
p=0.058**CAT Score**Day 28, n94199LS mean score (SE)14.75 (0.551)13.26 (0.378)LS mean CFB (SE)−0.26 (0.551)−1.75 (0.378) Treatment difference vs placebo, number (95% CI)\
 p-value--−1.49 (−2.81, −0.17)\
p=0.027Day 84, n87189LS mean score (SE)14.93 (0.594)12.83 (0.403)LS mean CFB (SE)−0.08 (0.594)−2.18 (0.403) Treatment difference vs placebo, number (95% CI)\
 p-value--−2.10 (−3.51, −0.68)\
p=0.004Day 168, n80179LS mean (SE)13.69 (0.648)13.01 (0.434)LS mean CFB score (SE)−1.32 (0.648)−2.00 (0.434) Treatment difference vs placebo, number (95% CI)\
 p-value-−0.68 (−2.22, 0.86)\
p=0.386[^5]

Health Outcomes {#S0003-S2004}
---------------

### SGRQ {#S0003-S2004-S3001}

CFB in SGRQ total score showed significantly greater improvements in the UMEC arm compared with the placebo arm at Days 28 and 84 ([Table 4](#T0004){ref-type="table"}). The odds of being a responder were statistically significantly in favor of UMEC compared with placebo on Day 84 (placebo n=33/91 \[36%\], UMEC n=98/194 \[51%\]; OR 1.7; 95% CI: 1.0, 2.9; p=0.042). At Day 28 (placebo n=36/91 \[40%\], UMEC n=95/188 \[51%\]; OR 1.4; 95% CI: 0.8, 2.5; p=0.186) and Day 168 (placebo n=45/92 \[49%\], UMEC n=104/195 \[53%\]; OR 1.1; 95% CI: 0.7, 1.9; p=0.633) the odds of being a responder were not significantly different between treatment groups.

### CAT {#S0003-S2004-S3002}

The CFB in CAT score showed statistically significant greater improvements in the UMEC arm compared with the placebo arm at Days 28 and 84 but not Day 168 ([Table 4](#T0004){ref-type="table"}). The odds of being a responder versus a non-responder were significantly in favor of UMEC over placebo at Day 84 (placebo n=31/94 \[33%\], UMEC n=102/199 \[51%\]; OR 1.9; 95% CI: 1.1, 3.3; p=0.017) but not at Day 28 (placebo n=41/94 \[44%\], UMEC n=103/199 \[52%\]; OR 1.2; 95% CI: 0.7, 2.0; p=0.490) or Day 168 (placebo n=38/94 \[40%\], UMEC n=10/199 \[50%\]; OR 1.3; 95% CI: 0.8, 2.2; p=0.324).

Safety {#S0003-S2005}
------

The incidence of on-treatment AEs was higher in the UMEC arm (n=122/205; 60%) compared with the placebo arm (n=56/101; 55%). The incidence of non-fatal SAEs, drug-related AEs, and AEs leading to withdrawal was similar between the treatment groups ([Table 5](#T0005){ref-type="table"}). The most common AE in both treatment groups was upper respiratory tract infections (placebo n=13/101 \[13%\]; UMEC n=25/205 \[12%\]; [Table 5](#T0005){ref-type="table"}). There were no drug-related fatal SAEs; one (\<1%) patient in the UMEC arm had a fatal SAE (sudden death), which was not considered to be drug related by the investigator.Table 5Summary of on-Treatment AEsPlacebo\
N=101UMEC\
N=205AE, n (%) On-treatment56 (55)122 (60) Drug-related7 (7)13 (6) Leading to permanent discontinuation of the study medication or withdrawal from the study6 (6)11 (5)Non-fatal SAE, n (%) On-treatment9 (9)15 (7) Post-treatment1 (\<1)1 (\<1) On-treatment drug-related2 (2)1 (\<1)Fatal SAE, n (%)01 (\<1) Drug-related00Most Frequent AEs (≥3% of Patients in Either Treatment Arm) n, (%) Upper respiratory tract infection13 (13)25 (12) Nasopharyngitis11 (11)19 (9) COPD5 (5)5 (2) Urinary tract infection3 (3)2 (\<1) Dizziness2 (2)6 (3) Blood glucose increased3 (3)2 (\<1) Benign prostatic hyperplasia3 (3)0[^6]

Discussion {#S0004}
==========

This is the first study of the efficacy and safety of UMEC monotherapy in patients of Asian origin. It provides clinically important data that builds on the evidence for the use of LAMA monotherapy in other patient populations with COPD.[@CIT0012],[@CIT0015],[@CIT0016] In this 24 weeks, randomized study of UMEC 62.5 mcg versus placebo in Asian patients with COPD, statistically significant improvements in favor of UMEC were demonstrated for lung function parameters, dyspnea (at Days 28 and 168), rescue medication use, and SGRQ and CAT at Days 28 and 84. No new safety concerns were raised in this population. The findings of the current study confirm and extend those of previous studies that have demonstrated the efficacy and safety of once-daily UMEC 62.5 mcg in patients with COPD that have not focused on Asian patients.[@CIT0012],[@CIT0015],[@CIT0016]

A change in trough FEV~1~ of 100 mL is considered to be the minimum clinically important difference perceived by patients with COPD.[@CIT0021] The FEV~1~ improvements demonstrated with UMEC in the current study exceeded this at all time points up to Day 169, and 6 hrs post dose on Day 1. In addition, statistically significant improvements were demonstrated in FVC for UMEC versus placebo, indicating a reduction in hyperinflation or air-trapping. These findings are consistent with those observed in other studies of once-daily UMEC 62.5 mcg in patients with COPD who were predominantly Caucasian.[@CIT0015],[@CIT0022]--[@CIT0024] While our study cannot be directly compared with studies conducted in predominantly Caucasian populations due to differences in eligibility criteria and study design (eg, study length), the correlation between lung function outcomes in a number of studies suggests minimal inter-ethnic differences in response to treatment with UMEC among Asian patients and those of other ethnicities.

Importantly, statistically significant improvements in favor of UMEC were seen in other clinically relevant endpoints, including TDI focal score and the proportion of TDI responders on Day 168. Again, these findings are in line with those seen in studies with predominately Caucasian populations.[@CIT0024] In the present study, symptom improvement was also demonstrated by the reduction in rescue medication use, which was statistically significant in favor of UMEC over placebo. There were also fewer patients with moderate or severe COPD exacerbations during 6 months of UMEC treatment compared with placebo, which is consistent with other studies performed in predominantly Caucasian populations.[@CIT0015],[@CIT0024]

Compared with placebo, improvement in health-related quality of life (HRQoL), measured by the SGRQ and CAT, was significantly greater with UMEC at Days 28 and 84 and the odds of a clinically significant response were also greater with UMEC versus placebo at Day 84. However, these clinically important differences were not maintained at Day 168 as for both HRQoL measures there was an unexpected increase in the placebo response that minimized the magnitude of the UMEC versus placebo benefit.

Current guidelines recommend LAMA or LABA monotherapy alone as initial treatment for symptomatic patients at a low risk of exacerbations.[@CIT0002] Similar to the current study, benefits in Asian patients with COPD have also been reported in studies of other LAMAs, such as TIO and glycopyrronium. In the 4-year UPLIFT study, patients receiving once-daily TIO 18 mcg demonstrated improvements in FEV~1~ compared with patients receiving placebo[@CIT0010] and in a subanalysis of Asian patients, the response to TIO was generally comparable between Asian patients and the total cohort, with improvements in lung function, HRQoL, and reductions in exacerbation frequency among those treated with TIO compared with control.[@CIT0025] Improvements with LAMA monotherapy in an Asian population were also shown in a 26-week, multicenter, double-blind, placebo-controlled, parallel-group study in predominantly Chinese patients with moderate-to-severe COPD, in which once-daily glycopyrronium 50 mcg significantly improved lung function, dyspnea, and health status compared with placebo.[@CIT0026]

The strength of this study lies in its robust design and the fact that it was conducted in a large, well-characterized Asian population with COPD at low risk of exacerbations. It therefore provides much needed evidence for how UMEC 62.5 mcg performs in this specific population. However, there are some limitations to consider. For example, there was a higher rate of withdrawals in the placebo arm compared with the UMEC arm, which may have led to a loss of differentiation between treatments. In addition, TDI response in the placebo group was unexpectedly high, although similar placebo effects have been demonstrated for TDI in previous studies.[@CIT0017],[@CIT0024] The underlying cause of these effects remains unclear, but may be related to the Hawthorne effect, a process by which study participants experience improved outcomes regardless of their treatment allocation.[@CIT0027] In addition, 95% of the patients in this study were male, which is consistent with a previous study in Asian patients with COPD[@CIT0018] but may limit generalizability of the findings to the broader patient population. Despite this, the study provides valuable data on the efficacy and safety of UMEC 62.5 mcg compared with placebo in a population of Asian patients with COPD, providing useful and relevant information for prescribing physicians in Asia.

Conclusions {#S0005}
===========

In Asian patients with COPD, compared with placebo, UMEC 62.5 mcg administered once-daily via the ELLIPTA inhaler over a 24-week treatment period resulted in statistically significant improvements in lung function and dyspnea throughout the study and HRQoL at Days 24 and 84, with no new safety concerns observed.

ELLIPTA is owned by or licensed to the GSK group of companies. Editorial support (in the form of writing assistance during development of the initial draft, assembling tables and figures, collating authors comments, grammatical editing, and referencing) was provided by Joanne Ashworth and Katie White, PhD, of Fishawack Indicia Ltd, UK, and was funded by GSK. This study was previously presented at the 23rd Congress of the Asian Pacific Society of Respirology, 29 November--2 December 2018, Taipei, Taiwan.
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